Phase III research
Biologic medicine effective against refractory psoriatic arthritis
Trial supports the use of ixekizumab as an option for patients who are unable to take TNF inhibitors.
Source: CID – ISM / Science Photo Library
There are limited treatment options for people with psoriatic arthritis who either do not respond to or are unable to take tumour necrosis factor (TNF) inhibitors.
In a phase III trial, published in The Lancet (online, 24 May 2017), 363 people with refractory psoriatic arthritis were randomly assigned to placebo or ixekizumab, a monoclonal antibody that targets interleukin 17A, administered every two or four weeks.
After 24 weeks, more people who received ixekizumab every four weeks had at least a 20% significant improvement in the American College of Rheumatology response criteria compared with those who received placebo (53% vs 20%). The same was also true of people who received ixekizumab every two weeks (48%).
The researchers conclude that ixekizumab, which has already been shown to be effective in treatment-naive patients, is an alternative option for difficult-to-treat psoriatic arthritis patients who have had an inadequate response, or intolerance, to TNF inhibitors.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202937
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£37.00Buy now